Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5798482 | 1.00 | MAPK1 (0.58) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL5798484 | 1.00 | MAPK1 (0.58) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL30268729 | 1.00 | MAPK1 (0.58) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL8939993 | 0.90 | ALDH1A1 (0.64) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL17595505 | 0.86 | MAPK1 (0.59) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL4712246 | 0.85 | MAPK1 (0.55) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL4633511 | 0.83 | MAPK1 (0.56) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL5641347 | 0.83 | MAPK1 (0.56) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL4633515 | 0.83 | MAPK1 (0.56) | MAPK1ALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL6155955 | 0.83 | ALDH1A1 (0.59) | MAPK1ALDH1A1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | KANEKA CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1553093-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-5663173-A | CENTRAL NERVOUS SYSTEM DISORDERS, COGNITION ACTIVATORS, PYCHOSES, ANTIDEPRESSANTS AND EATING DISORDERS | SYNTHELABO (FR) | 1997-09-02 | — | — | US | disclosed |
| EP-0748807-A1 | Derivatives of N-(1,4-diazabicyclo(2.2.2)-oct-2-yl)methyl benzamide, their preparation and their therapeutical use | SYNTHELABO (FR) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | OXER1, RCC2, CBR3 | MAPK1 925/4885ALDH1A1 538/4885KMT2A 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.